Supported by Grant [7] . Moreove r. the exoge nous addit ion of analogues of cG M P or cholenergic stimu li which presumably act to elevate int racellular concentrations of cGMP also augment mediator release [6 ] . The exact step or steps in the reaction seq uence of ge neration and release of mediators modulated by the cyclic nucleotides is unclear and may include both control over the generation of mediators as well as release. perhaps via alterations in the alignment of microtubles and microfi laments. An understanding of th e chemical and fum·tiona l nature of the specific facto rs released pro\'ides the basis fo r an approach to unra velling the mechanisms underlying pathobio logic alterati ons manirest by disease states . The preformed mediator histamine is formed from L-h istidin e and inactivated by oxidative deaminati on with or withom methylation [8] . In vivo h istamine is known to alter venula r permeabi lity and to stimulate the resp iratory irri tant receptor [9] and to constrict bronchial smoot h muscle.
ECF-A is also preformed [4 J and is an acid ic, approximately 400 mw te trapeptide [lOJ of limited heterogeneity . E CF -A preferent.ially a ttrac ts and chem otactically deactivate eosi nophils [111. It is suscept ibl e to pronase and subtilin digestion but resists trypsin or chym ot rypsi n degradation [12] . E CF-A p referentially attracts eosinophils a nd is the mos t potent eosinophil otactic factor when com pared to active site or complement der ived c he motactic facto rs [13] . Follow in g interaction with EC F-A, eosinophils reveal dimi nished responsiveness to subsequent chemotactic stimulation, termed deactiva t ion , a phenomenon presumed to allow attracted eosinophils to remain at a site and exert a regulatory function . SRS-A is an acidic sulfu r containing 300 mw lipid [14] inactivated by limpet [15] or human eosinophil [11] arylsulfatase. SRS-A can be found immediately prior to release in tissues following activation [16) . SRS-A has been presumed to originate in mast cells or basophils ba ed upon its generation by IgE dependent reaction in human mast cell-rich tissues [3. I i I. peri pheral blood leukocytes [l8], or ionophore activation of leukemic basophils [I). SRS-A can be appreciated intracellularly following levels of activation below t hreshold for histamine release [16) . and following greater degrees of challenge, release proceeds beyond the time of plateau for histamine or ECF-A release [16] . Furthermore, the release of SRS-A can be augmented markedl y by the addition of c:ysteine to the reaction medium [19) . SR -A may also be generated in rodent tis-'ues by a n 19Ga. neutrophil. and complementdependent mechanism [20] . SR -A in vivo contracts smooth muscle. enhances vascular permeability [21] , and decreases pulmonary compl ia nce [221. PAF. defined by its ability to mediate serotonin release from platelets. has been appreciated following IgE-dependent reactions in human lung [23) and peri pheral blood leukocyte suspension [24 1 and by calcium ionophore activation of human leukemic basophils. PAF generated by an IgG adependent reaction in the rat peritoneal cavity has an m w of :300 and is stable to arylsulfatase but sensi t ive to eosinophil phospholipase D enzymatic degradation [25) . The exact-functional properties of this factor in \'ivo a re unknown.
The possible fu ncti onal interrelationships of these chemical mediators are mainly speculative. It is known that histamine and SRS-A potentiate one a nother in bronchial smooth muscle trips [26) a nd may ac t synergi stically in vascular smooth muscle as well. It is also possible that these primary mediators may induce the product ion of such secondary mediators as prostaglandins or kinins . Finally. it should be noted that the potential for de. truction of three of these primary mediators is inherent in the properties of the fourth. That is. ECF-A. b~' attracting eosinophil. attracts and localizes to the site of mediator release MEDIATORS OF IMMEDIATE TYPE HYPERSENSITIVITY 621 a cell which contains histaminase to inactivate histamine [27] , arylsulfatase B to inactivate SRS-A [15] , and pho pholipa e D to inactivate PAF [28) .
